Alliance Wealth Advisors LLC UT Acquires 2,938 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Alliance Wealth Advisors LLC UT raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 14.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 23,992 shares of the biopharmaceutical company’s stock after purchasing an additional 2,938 shares during the period. Alliance Wealth Advisors LLC UT’s holdings in Gilead Sciences were worth $1,944,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. OFI Invest Asset Management bought a new stake in shares of Gilead Sciences during the third quarter valued at approximately $26,000. Tompkins Financial Corp increased its position in shares of Gilead Sciences by 223.1% during the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 241 shares in the last quarter. Fortitude Family Office LLC bought a new stake in shares of Gilead Sciences during the fourth quarter valued at approximately $29,000. Rakuten Securities Inc. bought a new stake in shares of Gilead Sciences during the fourth quarter valued at approximately $33,000. Finally, Financial Connections Group Inc. bought a new stake in shares of Gilead Sciences during the fourth quarter valued at approximately $40,000. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the transaction, the insider now owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. UBS Group cut their target price on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. HSBC raised shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price for the company in a research report on Wednesday. Morgan Stanley cut their target price on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a research report on Friday. TD Cowen cut their target price on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research report on Friday. Finally, Mizuho dropped their price target on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday, February 22nd. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $83.87.

Gilead Sciences Price Performance

Shares of GILD traded up $0.15 during trading hours on Friday, reaching $65.42. 12,382,425 shares of the stock traded hands, compared to its average volume of 6,443,315. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. Gilead Sciences, Inc. has a 52-week low of $64.63 and a 52-week high of $87.86. The company’s 50-day moving average price is $71.28 and its two-hundred day moving average price is $76.25. The company has a market cap of $81.45 billion, a P/E ratio of 181.72, a price-to-earnings-growth ratio of 1.17 and a beta of 0.19.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 23.08%. The company had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. During the same quarter in the previous year, the company earned $1.37 EPS. Gilead Sciences’s revenue for the quarter was up 5.3% on a year-over-year basis. On average, analysts anticipate that Gilead Sciences, Inc. will post 4.2 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 4.71%. The ex-dividend date of this dividend is Friday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.